JP5801406B2 - メラニン形成に関与しているアドレナリン受容体遺伝子発現を調節するスクリーニング方法 - Google Patents
メラニン形成に関与しているアドレナリン受容体遺伝子発現を調節するスクリーニング方法 Download PDFInfo
- Publication number
- JP5801406B2 JP5801406B2 JP2013535148A JP2013535148A JP5801406B2 JP 5801406 B2 JP5801406 B2 JP 5801406B2 JP 2013535148 A JP2013535148 A JP 2013535148A JP 2013535148 A JP2013535148 A JP 2013535148A JP 5801406 B2 JP5801406 B2 JP 5801406B2
- Authority
- JP
- Japan
- Prior art keywords
- adrβ1
- receptor
- test agent
- skin
- screening method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
この実験では、0.5mLのB16−F1細胞を29.5mLのB16−F1培養培地に加えて2つの別個のT−150フラスコに入れ、コンフルエントに近くなるまで(〜80%)増殖させる。培養培地B16−F1は、次の表1に示されている以下の成分を含む。
Claims (7)
- 色素沈着した皮膚の外観を変更するのに有効な少なくとも1つの試験薬剤を特定するためのスクリーニング方法であって、
ADRβ1受容体を含む細胞、細胞培養物、又はバルク細胞を前記試験薬剤と接触させる工程であって、前記試験薬剤は、パルミトイル化ペプチドである工程と、
前記試験薬剤と前記ADRβ1受容体との結合相互作用に基づき、前記試験薬剤が、色素沈着した皮膚の外観を変更するのに適した有効なADRβ1受容体アンタゴニストであるかどうかを判定する工程と、
を含み、
試験薬剤が、1000ppm未満の半値抑制濃度を示す場合に、該試験薬剤が有効なADRβ1受容体アンタゴニストであるとする、スクリーニング方法。 - 前記ADRβ1受容体アンタゴニストに翻訳されるADRβ1遺伝子が、少なくても2の倍率変化値及び0.05未満のP値を有すると統計分析によって立証されるアップレギュレーションを明確に示す、請求項1に記載のスクリーニング方法。
- 前記ADRβ1受容体アンタゴニストが、ADRβ2受容体のアンタゴニストとしても作用する、請求項1に記載のスクリーニング方法。
- 第2の細胞、第2の細胞培養物、又は第2のバルク細胞のセットを前記試験薬剤と接触させる工程と、前記試験薬剤が前記ADRβ2受容体のアンタゴニストである場合に、前記試験薬剤が、色素沈着した皮膚の外観を変更するのに有効であると判定する工程とを更に含む、請求項1に記載のスクリーニング方法。
- メラニンの生成を調節し、それによってヒトの皮膚における加齢によるシミの外観を低減する前記ADRβ1受容体アンタゴニストの能力を、前記ADRβ1受容体アンタゴニストのアンタゴニスト活性と相関させる工程を更に含む、請求項1に記載のスクリーニング方法。
- B16細胞アッセイ又は皮膚モデルからなる群から選択されるメラニン合成アッセイで前記試験薬剤を評価する工程を更に含む、請求項1に記載のスクリーニング方法。
- ADRβ1受容体アンタゴニストとADRβ1受容体との間の結合相互作用に応じて発光シグナルが生成される、請求項1に記載のスクリーニング方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40633810P | 2010-10-25 | 2010-10-25 | |
US61/406,338 | 2010-10-25 | ||
PCT/US2011/057608 WO2012061100A2 (en) | 2010-10-25 | 2011-10-25 | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013541342A JP2013541342A (ja) | 2013-11-14 |
JP5801406B2 true JP5801406B2 (ja) | 2015-10-28 |
Family
ID=44936538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013535148A Active JP5801406B2 (ja) | 2010-10-25 | 2011-10-25 | メラニン形成に関与しているアドレナリン受容体遺伝子発現を調節するスクリーニング方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10267796B2 (ja) |
EP (1) | EP2633314B1 (ja) |
JP (1) | JP5801406B2 (ja) |
CN (1) | CN103201625B (ja) |
CA (2) | CA3006098C (ja) |
WO (1) | WO2012061100A2 (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9671410B2 (en) | 2011-01-16 | 2017-06-06 | The Procter & Gamble Company | Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin |
CN104780897A (zh) | 2013-03-15 | 2015-07-15 | 宝洁公司 | 化妆品组合物和用于抑制黑素合成的方法 |
CA2890512C (en) * | 2013-05-01 | 2017-04-25 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
WO2014182996A2 (en) | 2013-05-10 | 2014-11-13 | The Procter & Gamble Company | Modular emulsion-based product differentiation |
WO2014182995A2 (en) | 2013-05-10 | 2014-11-13 | The Procter & Gamble Company | Modular emulsion-based product differentiation |
JP2016521285A (ja) | 2013-05-10 | 2016-07-21 | ザ プロクター アンド ギャンブル カンパニー | 標準エマルジョン系生成物の差別化 |
CN103735422A (zh) * | 2013-11-05 | 2014-04-23 | 苏州冉新生物技术有限公司 | 祛斑液 |
JP6513795B2 (ja) * | 2014-09-12 | 2019-05-15 | ザ プロクター アンド ギャンブル カンパニー | スキンケア組成物の製造方法 |
US10966916B2 (en) | 2014-11-10 | 2021-04-06 | The Procter And Gamble Company | Personal care compositions |
CN107106429B (zh) | 2014-11-10 | 2021-06-29 | 宝洁公司 | 具有两种有益相的个人护理组合物 |
EP3217949B1 (en) | 2014-11-10 | 2020-06-17 | The Procter and Gamble Company | Personal care compositions with two benefit phases |
EP3288529A1 (en) | 2015-05-01 | 2018-03-07 | The Procter and Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
WO2016178945A1 (en) | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
WO2017004100A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Encapsulated particles comprising nicotinamide riboside |
WO2017004101A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Skin care compositions comprising particles with nicotinamide riboside and methods of using the same |
CA3010730C (en) | 2016-01-11 | 2021-02-16 | The Procter & Gamble Company | Method of treating a skin condition and compositions therefor |
US20170296456A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Products and methods for treating periorbital dyschromia |
US10493020B2 (en) | 2016-04-14 | 2019-12-03 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
US20170296457A1 (en) | 2016-04-14 | 2017-10-19 | The Procter & Gamble Company | Products and methods for treating periorbital dyschromia |
EP3641725A1 (en) | 2017-06-23 | 2020-04-29 | The Procter and Gamble Company | Composition and method for improving the appearance of skin |
EP3697375B1 (en) | 2017-10-20 | 2021-12-01 | The Procter & Gamble Company | Aerosol foam skin cleanser |
EP3697374B1 (en) | 2017-10-20 | 2022-02-16 | The Procter & Gamble Company | Aerosol foam skin cleanser |
WO2019226722A1 (en) | 2018-05-22 | 2019-11-28 | The Procter & Gamble Company | System and method for identifying connections between perturbagens and genes associated with a skin condition |
US10874600B2 (en) | 2018-06-18 | 2020-12-29 | The Procter & Gamble Company | Method for degrading bilirubin in skin |
EP3817717A1 (en) | 2018-07-03 | 2021-05-12 | The Procter & Gamble Company | Method of treating a skin condition |
CN113015904B (zh) | 2018-11-29 | 2024-06-18 | 宝洁公司 | 用于筛选个人护理产品的方法 |
WO2020142212A1 (en) | 2019-01-03 | 2020-07-09 | The Procter & Gamble Company | Personalized skin care system |
US11786451B2 (en) | 2019-06-28 | 2023-10-17 | The Procter & Gamble Company | Skin care composition |
US20200405621A1 (en) | 2019-06-28 | 2020-12-31 | The Procter & Gamble Company | Skin Care Composition |
WO2021150807A1 (en) | 2020-01-24 | 2021-07-29 | The Procter & Gamble Company | Skin care composition |
JP2023528616A (ja) | 2020-06-01 | 2023-07-05 | ザ プロクター アンド ギャンブル カンパニー | ビタミンb3化合物の皮膚への浸透を改善する方法 |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
KR102493245B1 (ko) * | 2020-10-30 | 2023-01-30 | 주식회사 지엠엑스 | 카베디롤을 유효성분으로 포함하는 피부 미백용 조성물 |
EP4259068A1 (en) | 2020-12-14 | 2023-10-18 | The Procter & Gamble Company | Method of manufacturing cosmetic compositions comprising sucrose esters and solvents |
CN116583264A (zh) | 2020-12-14 | 2023-08-11 | 宝洁公司 | 包含蔗糖酯和溶剂的化妆品组合物 |
CN116981439A (zh) | 2020-12-14 | 2023-10-31 | 宝洁公司 | 处理皮肤中氧化应激的方法及其组合物 |
WO2022132689A1 (en) | 2020-12-14 | 2022-06-23 | The Procter & Gamble Company | Stable skin care emulsion and methods of using the same |
US11571378B2 (en) | 2021-01-22 | 2023-02-07 | The Procter & Gamble Company | Skin care composition and method of using the same |
US11771637B2 (en) | 2021-01-22 | 2023-10-03 | The Procter & Gamble Company | Skin care composition and method of using the same |
US20220378679A1 (en) | 2021-05-30 | 2022-12-01 | The Procter & Gamble Company | Cosmetic product comprising a cosmetic composition contained in an applicator |
WO2023056029A1 (en) * | 2021-10-01 | 2023-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Beta3-adrenergic agonists for treatment of disorders of hair growth |
WO2023081670A1 (en) | 2021-11-03 | 2023-05-11 | The Procter & Gamble Company | Cosmetic product comprising oil discontinuous phase and method of use thereof |
US20230137524A1 (en) | 2021-11-03 | 2023-05-04 | The Procter & Gamble Company | Cosmetic product comprising oil discontinuous phase |
US20230165768A1 (en) | 2021-11-29 | 2023-06-01 | The Procter & Gamble Company | Skin care composition |
WO2023097320A1 (en) | 2021-11-29 | 2023-06-01 | The Procter & Gamble Company | Method of improving the appearance of skin |
WO2023097321A1 (en) | 2021-11-29 | 2023-06-01 | The Procter & Gamble Company | Skin care composition comprising a hydroxycinnamic acid |
WO2023122465A2 (en) | 2021-12-21 | 2023-06-29 | The Procter & Gamble Company | Cosmetic composition comprising mica and lauroyl lysine |
WO2023122467A1 (en) | 2021-12-21 | 2023-06-29 | The Procter & Gamble Company | Cosmetic composition comprising vitamin b3 compound and lauroyl lysine |
WO2023122466A2 (en) | 2021-12-21 | 2023-06-29 | The Procter & Gamble Company | Cosmetic composition comprising sucrose ester and lauroyl lysine |
US20230233441A1 (en) | 2022-01-24 | 2023-07-27 | The Procter & Gamble Company | Skin care composition containing sodium hyaluronate and method of making the same |
US20230233440A1 (en) | 2022-01-24 | 2023-07-27 | The Procter & Gamble Company | Skin care serum containing sodium hyaluronate |
WO2023245094A1 (en) | 2022-06-15 | 2023-12-21 | The Procter & Gamble Company | Skin care emulsion composition with clean polymers and emulsifiers |
US20230404898A1 (en) | 2022-06-15 | 2023-12-21 | The Procter & Gamble Company | Skin care composition with clean polymer |
US20230404864A1 (en) | 2022-06-15 | 2023-12-21 | The Procter & Gamble Company | Clean skin care composition |
WO2024073219A1 (en) | 2022-09-28 | 2024-04-04 | The Procter & Gamble Company | Stable skin care compositions containing a retinoid |
US20240139084A1 (en) | 2022-10-12 | 2024-05-02 | The Procter & Gamble Company | Cosmetic composition comprising silica and lauroyl lysine |
WO2024081034A1 (en) | 2022-10-12 | 2024-04-18 | The Procter & Gamble Company | Cosmetic composition comprising polyacrylate crosspolymer-6, and silica and/or lauroyl lysine |
WO2024081033A1 (en) | 2022-10-12 | 2024-04-18 | The Procter & Gamble Company | Cosmetic composition comprising polyacrylate crosspolymer-6 and high hlb nonionic surfactant |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5462856A (en) * | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
AU7639796A (en) * | 1995-11-30 | 1997-06-19 | Kissei Pharmaceutical Co. Ltd. | Novel drug for relieving pain and promoting the removal of calculi in urolithiasis |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US7081482B2 (en) * | 1999-11-30 | 2006-07-25 | Alcon, Inc. | Use of β-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina |
US20040072287A1 (en) * | 2001-10-26 | 2004-04-15 | Carina Tan | Cell lines expressing a mch receptor |
FR2843963B1 (fr) * | 2002-08-30 | 2004-10-22 | Sederma Sa | Nouvelles molecules derivees de la noraporphine |
US7189419B2 (en) * | 2002-12-17 | 2007-03-13 | Avon Products, Inc. | Use of active extracts to lighten skin, lips, hair, and/or nails |
US20060074097A1 (en) * | 2003-03-04 | 2006-04-06 | Bissett Donald L | Regulation of mammalian keratinous tissue using hexamidine compositions |
JP4256389B2 (ja) * | 2003-11-17 | 2009-04-22 | セダーマ | テトラペプチドとトリペプチドの混合物を含む組成物 |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
JP5670755B2 (ja) * | 2008-03-12 | 2015-02-18 | ザ ロックフェラー ユニバーシティ | 翻訳プロファイリング及び分子表現型解析のための方法及び組成物 |
-
2011
- 2011-10-21 US US13/278,465 patent/US10267796B2/en active Active
- 2011-10-25 CN CN201180050544.3A patent/CN103201625B/zh active Active
- 2011-10-25 WO PCT/US2011/057608 patent/WO2012061100A2/en active Application Filing
- 2011-10-25 EP EP11781911.0A patent/EP2633314B1/en active Active
- 2011-10-25 CA CA3006098A patent/CA3006098C/en active Active
- 2011-10-25 CA CA2815665A patent/CA2815665C/en not_active Expired - Fee Related
- 2011-10-25 JP JP2013535148A patent/JP5801406B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20120197016A1 (en) | 2012-08-02 |
US10267796B2 (en) | 2019-04-23 |
CN103201625A (zh) | 2013-07-10 |
CA3006098A1 (en) | 2012-05-10 |
WO2012061100A3 (en) | 2012-06-21 |
CN103201625B (zh) | 2016-09-14 |
JP2013541342A (ja) | 2013-11-14 |
EP2633314B1 (en) | 2019-11-27 |
EP2633314A2 (en) | 2013-09-04 |
CA2815665C (en) | 2018-07-10 |
WO2012061100A2 (en) | 2012-05-10 |
CA3006098C (en) | 2021-02-16 |
CA2815665A1 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5801406B2 (ja) | メラニン形成に関与しているアドレナリン受容体遺伝子発現を調節するスクリーニング方法 | |
JP6563889B2 (ja) | 色素沈着過剰状態の遺伝子発現シグネチャーを生成する方法 | |
JP2016019531A (ja) | 皮膚サンプルの年齢範囲の決定方法 | |
US9964534B2 (en) | Method of making a skin care composition | |
CN100562748C (zh) | 以斑点部位亢进基因群为指标而预知皮肤斑点形成的方法、筛选皮肤斑点形成抑制物的方法 | |
DE10260931B4 (de) | Verfahren zur Bestimmung der Homeostase behaarter Haut | |
JP2019529462A (ja) | Tnfrsf 14抑制物質を含む皮膚美白用組成物及びtnfrsf 14抑制物質のスクリーニング方法 | |
JP2018027920A (ja) | 色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 | |
EP3302716B1 (en) | Methods for identifying circadian rhythm-dependent cosmetic agents for skin care compositions | |
WO2005033710A1 (ja) | しみ部位亢進遺伝子群を指標とした皮膚しみ形成予知方法、皮膚しみ形成抑制剤のスクリーニング方法 | |
EP3455370B1 (en) | Method of identifying cosmetic agents for moisturizing skin | |
US20160122820A1 (en) | Screening Method for Identifying Active Agents | |
CN114269945A (zh) | 鉴定纤维化过程的调节物的方法 | |
EP3191608A1 (en) | Genetic assay for skin pigmentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150728 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150826 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5801406 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |